ASCO 2017: Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression

Posted by: | July 11, 2017 | Comments

shutterstock_183635540-lymphocytes

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, reported Wargo et al at the 2017 ASCO Annual Meeting (Abstract 3008).

Their study of fecal samples from 105 patients treated with immune checkpoint blockade indicates that certain characteristics of patients’ microbiomes correlate with slower disease progression, while other qualities are associated with rapid worsening of the disease.

“Greater diversity of bacteria in the gut microbiome is associated with both a higher response rate to treatment and longer progression-free survival,” said study leader Jennifer Wargo, MD, Associate Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center.

Find Out the Details at: The ASCO Post






Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required



Terms & Conditions | Privacy Policy | © 2016 The Translational Microbiome Research Forum